New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - ketamine hydrochloride 115.34 mg/ml equivalent to ketamine 100 mg/ml - solution for injection - 100 mg/ml - active: ketamine hydrochloride 115.34 mg/ml equivalent to ketamine 100 mg/ml excipient: nitrogen water for injection - ketamine-baxter is recommended: 1. as the sole anaesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation. ketamine-baxter is best suited for short procedures and it can be used with additional doses, for longer procedures; 2. for the induction of anaesthesia prior to the administration of other general anaesthetic agents; 3. to supplement low-potency agents, such as nitrous oxide.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 29.8 g/l; sodium chloride, quantity: 9 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - sodium chloride, quantity: 2.92 g/l; potassium chloride, quantity: 7.46 g/l - injection, intravenous infusion - excipient ingredients: water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

Australia - English - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 1.5 g/l; sodium chloride, quantity: 9 g/l - injection, solution - excipient ingredients: hydrochloric acid; water for injections - the baxter potassium chloride and sodium chloride intravenous infusion is indicated as a source of water and to restore electrolyte balance as required by the patient's clinical condition, such as hypokalaemia.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 10% - solution for infusion - 10 % - active: glucose monohydrate 10% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 25% - solution for infusion - 25 % - active: glucose monohydrate 25% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 5% - solution for infusion - 5 % - active: glucose monohydrate 5% - isotonic (glucose 5%) infusion solutions are mainly indicated for: - whenever non-electrolyte fluid replacement is required, - as a vehicle for drug delivery, provided that the added components are compatible with glucose.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 50% - solution for infusion - 50 % - active: glucose monohydrate 50% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 70% - solution for infusion - 70 % - active: glucose monohydrate 70% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.